Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

F Ziemssen, N Feltgen, F G Holz, R Guthoff, A Ringwald, T Bertelmann, A Wiedon, C Korb, OCEAN study group, F Ziemssen, N Feltgen, F G Holz, R Guthoff, A Ringwald, T Bertelmann, A Wiedon, C Korb, OCEAN study group

Abstract

Background: While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs.

Methods: The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO). Baseline patient characteristics were compared by indication within the OCEAN cohort. Furthermore, the characteristics were set in reference to those of published RCTs in the same indications. Confidence intervals (CIs) were calculated and assessed for statistically significant differences as indicated by non-overlapping CIs.

Results: Patient characteristics in the NIS OCEAN were evaluated for 3,614 patients with nAMD, 1,211 with DME, 204 with BRVO and 121 with CRVO. Between these groups, significant differences in mean age, gender distributions, and mean baseline VA were seen, reflecting known differences between the indications. Compared to the patient characteristics of published RCTs (trials selected by literature search: nAMD: 13 RCTs, DME: 9, RVO: 5), the OCEAN patients' mean age was significantly higher in every indication. The gender distributions across the trials were comparable, with only few differences between OCEAN and the RCTs. Regarding the mean baseline VA, notable differences were found in nAMD and in DME, with VA significantly higher in some RCTs and lower in others.

Conclusions: The described differences underline the complementarity of NISs and RCTs. OCEAN covers a broader spectrum and more variability of patients than do RCTs. As baseline values may have impact on the treatment response (ceiling effect), there is an ongoing need for research in all patient subgroups. Country-specific assessments of patient populations can better reflect the real-world situation. NISs can deliver insights that RCTs may not, as NISs can include non-typical patients, patients with comorbidities, a broader age spectrum and patients of various disease stages.

Trial registration: The NIS OCEAN was registered on www.clinicaltrials.gov (identifier: NCT02194803 ).

Keywords: Anti-VEGF; Ceiling effect; DME; Demographic characteristics; Epidemiology; NAMD; Non-interventional study; RVO.

Figures

Fig. 1
Fig. 1
Start dates of randomized controlled trials by indication. Legend: RCT start dates shown in relation to EMA and FDA ophthalmological marketing authorisation dates for Eylea®, Lucentis® and Macugen®. For sources of details and study periods for the RCTs see Additional file 2: Table S2. Abbreviations: BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; EMA: European Medicines Agency; FDA: US Food and Drug Administration; nAMD: neovascular age-related macular degeneration; RCT: randomized controlled trial; RVO: retinal vein occlusion
Fig. 2
Fig. 2
Baseline age distribution in OCEAN and patient age for OCEAN and RCTs, by indication. Legend: Age distribution in years by age group for OCEAN and mean age in years (with SD) for OCEAN and RCTs. Mean age is given overall per study (black square) and as mean with SD for each individual treatment group (grey circles with error bars). If the mean was not available, the median is shown (grey squares) with 25th/75th percentiles. The data for the individual treatment groups of each RCT are shown in the same order from top to bottom as the treatment groups are presented in Tables 2, 3, 4. ano SD available bData provided as median (25th, 75th percentile). cData provided for number of eyes, not number of patients. Abbreviations: BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; nAMD: neovascular age-related macular degeneration; RCT: randomized controlled trial; SD: standard deviation
Fig. 3
Fig. 3
Gender distribution in OCEAN study and in selected RCTs, by indication. Legend: Proportion of female patients (red) and male patients (blue) at baseline. aHatched columns: Gender group not explicitly provided in source data; data for respective other gender used for calculation of percentage (may include missing/unavailable data). bData provided for number of eyes, not number of patients. Abbreviations: BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; N: number of patients; nAMD: neovascular age-related macular degeneration; RCT: randomized controlled trial
Fig. 4
Fig. 4
Baseline visual acuity distribution in OCEAN and visual acuity for OCEAN and RCTs, by indication. Legend: Visual acuity distribution in ETDRS letter analogues by group for OCEAN and mean visual acuity (in ETDRS letter analogues with SD) for OCEAN and RCTs. Mean visual acuity is given overall per study (black square) and as mean with SD for each individual treatment group (grey circles with error bars). If the mean was not available, the median is shown (grey square) with 25th/75th percentiles. The data for the individual treatment groups of each RCT are shown in the same order from top to bottom as the treatment groups are presented in Tables 2, 3, 4. aThe visual acuity results for SAILOR are provided for four treatment groups. bData provided as median (25th, 75th percentile). c Data provided for number of eyes, not number of patients. Abbreviations: BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; DME: diabetic macular oedema; ETDRS: Early Treatment Diabetic Retinopathy Study; nAMD: neovascular age-related macular degeneration; RCT: randomized controlled trial; SD: standard deviation

References

    1. Garrison LP, Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–335. doi: 10.1111/j.1524-4733.2007.00186.x.
    1. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118(12):1294–1303. doi: 10.1161/CIRCULATIONAHA.107.703579.
    1. Nyman SR, Victor CR. Older people’s participation in and engagement with falls prevention interventions in community settings: an augment to the Cochrane systematic review. Age Ageing. 2012;41(1):16–23. doi: 10.1093/ageing/afr103.
    1. Barnett J, Aguilar S, Brittner M, Bonuck K. Recruiting and retaining low-income, multi-ethnic women into randomized controlled trials: successful strategies and staffing. Contemp Clin Trials. 2012;33(5):925–932. doi: 10.1016/j.cct.2012.06.005.
    1. Abraham NS, Young JM, Solomon MJ. A systematic review of reasons for nonentry of eligible patients into surgical randomized controlled trials. Surgery. 2006;139(4):469–483. doi: 10.1016/j.surg.2005.08.014.
    1. Olson MK. Are novel drugs more risky for patients than less novel drugs? J Health Econ. 2004;23(6):1135–1158. doi: 10.1016/j.jhealeco.2004.03.007.
    1. Crowther M. Phase 4 research: what happens when the rubber meets the road? Hematology Am Soc Hematol Educ Program. 2013;2013:15–18.
    1. ABPI . Demonstrating value with real world data: a practical guide. 2011.
    1. Rees A, Zekite A, Bunce C, Patel PJ. How many people in England and wales are registered partially sighted or blind because of age-related macular degeneration? Eye (Lond) 2014;28(7):832–837. doi: 10.1038/eye.2014.103.
    1. Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, Cook DG, Owen CG. Incidence of late-stage Age-related macular degeneration in american whites: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(1):85–93. doi: 10.1016/j.ajo.2015.04.003.
    1. Korb CA, Kottler UB, Wolfram C, Hoehn R, Schulz A, Zwiener I, Wild PS, Pfeiffer N, Mirshahi A. Prevalence of age-related macular degeneration in a large european cohort: results from the population-based Gutenberg health study. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1403–1411. doi: 10.1007/s00417-014-2591-9.
    1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi: 10.2337/dc11-1909.
    1. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014;2014:724780. doi: 10.1155/2014/724780.
    1. Demographischer Wandel in Deutschland. 2011. . Accessed 09 May 2016.
    1. Mayor E. Gender roles and traits in stress and health. Front Psychol. 2015;6:779. doi: 10.3389/fpsyg.2015.00779.
    1. Bertakis KD, Azari R. Patient gender differences in the prediction of medical expenditures. J Womens Health (Larchmt) 2010;19(10):1925–1932. doi: 10.1089/jwh.2009.1448.
    1. Lee AY, Lee CS, Butt T, Xing W, Johnston RL, Chakravarthy U, Egan C, Akerele T, McKibbin M, Downey L, et al. UK AMD EMR USERS GROUP REPORT V: benefits of initiating Ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol. 2015;99(8):1045–1050. doi: 10.1136/bjophthalmol-2014-306229.
    1. Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, Chen CY, Marsiglia M, Boddu S, Freund KB. Baseline predictors for good versus poor visual outcomes in the treatment of neovascular Age-related macular degeneration with Intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2015;56(9):5040–5047. doi: 10.1167/iovs.15-16494.
    1. Krause L, Yousif T, Pohl K. An epidemiological study of neovascular age-related macular degeneration in Germany. Curr Med Res Opin. 2013;29(10):1391–1397. doi: 10.1185/03007995.2013.832184.
    1. Raum P, Lamparter J, Ponto KA, Peto T, Hoehn R, Schulz A, Schneider A, Wild PS, Pfeiffer N, Mirshahi A. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: results from the Gutenberg health study. PLoS ONE. 2015;10(6):e0127188. doi: 10.1371/journal.pone.0127188.
    1. Hammes HP, Welp R, Kempe HP, Wagner C, Siegel E, Holl RW. Risk factors for retinopathy and DME in type 2 diabetes-results from the German/Austrian DPV database. PLoS ONE. 2015;10(7):e0132492. doi: 10.1371/journal.pone.0132492.
    1. Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, Lackner K, Pfeiffer N, Mirshahi A. Prevalence and risk factors of retinal vein occlusion: the Gutenberg health study. J Thromb Haemost. 2015;13(7):1254–1263. doi: 10.1111/jth.12982.
    1. Obesity and overweight . Factsheet N°311. 2015.
    1. Gesundheitsberichterstattung des Bundes. Tabelle “Verteilung der Bevölkerung auf Body-mass-Index-Gruppen in Prozent. Gliederungsmerkmale: Jahre, Deutschland, Alter, Geschlecht, Body-mass-index für 2013. 2014. . Accessed 09 May 2016.
    1. Deutscher Gesundheitsbericht Diabetes 2015 - Die Bestandsaufnahme. 2015. . Accessed 09 May 2016.
    1. Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L. Influence of glycosylated hemoglobin on the efficacy of Ranibizumab for diabetic macular edema: a post Hoc analysis of the RIDE/RISE trials. Ophthalmology. 2015;122(8):1573–1579. doi: 10.1016/j.ophtha.2015.04.029.
    1. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population--the european medicines Agency’s geriatric medicines strategy. N Engl J Med. 2012;367(21):1972–1974. doi: 10.1056/NEJMp1209034.
    1. Mortality and life expectancy statistics. 2015. . Accessed 09 May 2016.
    1. Weimer K, Enck P. Traditional and innovative experimental and clinical trial designs and their advantages and pitfalls. Handb Exp Pharmacol. 2014;225:237–272. doi: 10.1007/978-3-662-44519-8_14.
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/NEJMoa054481.
    1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi: 10.1056/NEJMoa062655.
    1. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145(2):239–248. doi: 10.1016/j.ajo.2007.10.004.
    1. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of Ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731–1739. doi: 10.1016/j.ophtha.2009.05.024.
    1. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A. Efficacy and safety of monthly versus quarterly Ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–839. doi: 10.1016/j.ophtha.2010.09.004.
    1. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ. 2010;340:c2459. doi: 10.1136/bmj.c2459.
    1. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267. doi: 10.1016/S0140-6736(13)61501-9.
    1. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. doi: 10.1016/j.ophtha.2013.08.011.
    1. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M. Ferris FLr. Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi: 10.1016/j.ophtha.2012.03.053.
    1. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schonherr U, Haas A, Ansari-Shahrezaei S, Binder S. A randomised double-masked trial comparing the visual outcome after treatment with Ranibizumab or Bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266–271. doi: 10.1136/bjophthalmol-2012-302391.
    1. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol. Ophthalmology. 2015;122(1):146–52. doi: 10.1016/j.ophtha.2014.07.041.
    1. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G. Ranibizumab versus Bevacizumab for neovascular Age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120(11):2300–2309. doi: 10.1016/j.ophtha.2013.06.020.
    1. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg Ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056. doi: 10.1016/j.ophtha.2012.10.014.
    1. Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, Beck RW, Bressler SB, Ferris FL, 3rd, Glassman AR, et al. Randomized trial evaluating short-term effects of Intravitreal Ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina (Philadelphia, Pa) 2011;31(6):1009–1027. doi: 10.1097/IAE.0b013e318217d739.
    1. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, 3rd, Friedman SM, Glassman AR, Miller KM, et al. Randomized trial evaluating Ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077. doi: 10.1016/j.ophtha.2010.02.031.
    1. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, et al. A prospective randomized trial of Intravitreal Bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086. doi: 10.1016/j.ophtha.2010.03.045.
    1. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039.
    1. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, et al. The RESTORE study: Ranibizumab Monotherapy or combined with laser versus laser Monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. doi: 10.1016/j.ophtha.2011.01.031.
    1. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi: 10.1016/j.ophtha.2014.05.006.
    1. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi: 10.1056/NEJMoa1414264.
    1. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–1112. doi: 10.1016/j.ophtha.2010.02.021.
    1. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–544. doi: 10.1016/j.ophtha.2014.08.031.
    1. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–1133. doi: 10.1016/j.ophtha.2010.02.022.
    1. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429–437. doi: 10.1016/j.ajo.2012.09.026.
    1. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, et al. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284. doi: 10.1136/bjophthalmol-2012-301504.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する